Evidence map›Paper›PMID 38016924›Full record

ArticleEpilepsia open2024

Identification of metabolic biomarkers of chronic vagus nerve stimulation (VNS) in subjects with drug-resistant epilepsy (DRE).

Claudia Manca, Roberta Coa, Elisabetta Murru, Gianfranca Carta, Giovanni Pinna, Roberto Sanfilippo, Lorenzo Polizzi, Marco Pistis, Paolo Follesa, Monica Puligheddu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Epilepsia open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Claudia MancaDepartment of Biomedical Sciences, Division of Physiology, University of Cagliari, Cagliari, Italy.ORCID 0000-0002-4081-9550
Roberta CoaCenter for the Diagnosis and Treatment of Adult Epilepsy, Neurology Unit, AOU Cagliari, Cagliari, Italy.ORCID 0000-0001-9709-9585
Elisabetta MurruDepartment of Biomedical Sciences, Division of Physiology, University of Cagliari, Cagliari, Italy.
Gianfranca CartaDepartment of Biomedical Sciences, Division of Physiology, University of Cagliari, Cagliari, Italy.
Giovanni PinnaSC Neurosurgery, Neuroscience and Rehabilitation Department, San Michele Hospital, ARNAS G. Brotzu, Cagliari, Italy.
Roberto SanfilippoSC Vascular Surgery, AOU Cagliari, Cagliari, Italy.
Lorenzo PolizziCenter for the Diagnosis and Treatment of Adult Epilepsy, Neurology Unit, AOU Cagliari, Cagliari, Italy.
Marco PistisDepartment of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.
Paolo FollesaDepartment of Life and Environmental Sciences, Section of Neuroscience and Anthropology, University of Cagliari, Cagliari, Italy.
Monica PulighedduCenter for the Diagnosis and Treatment of Adult Epilepsy, Neurology Unit, AOU Cagliari, Cagliari, Italy.
Sebastiano BanniDepartment of Biomedical Sciences, Division of Physiology, University of Cagliari, Cagliari, Italy.
University of Cagliari · ITAzienda Ospedaliera G. Brotzu · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuromodulation by means of vagus nerve stimulation (VNS) therapy, reduces seizure frequency and improves quality of life in subjects with drug-resistant epilepsy (DRE), yet its molecular mechanism remains unclear. This study investigates the impact of chronic VNS on lipid bioactive metabolites and fatty acids (FA) in the plasma and red blood cells of seven subjects with DRE. By measuring expression levels of peroxisome proliferator-activated receptor α (PPARα) and sirtuin1 (SIRT1) genes-key regulators in energy and lipid metabolism-and lipid profiles before and after various stages of VNS, this study identifies potential mechanisms by which VNS may reduce seizure frequency. Blood samples collected before VNS device implantation, after acute VNS stimulus, and following gradual intensity increments up to therapeutic levels revealed that VNS increases SIRT1 and PPARα expression and erythrocyte concentrations of PPARα ligands. Additionally, we observe reduced de novo lipogenesis biomarkers in erythrocytes, indicating that VNS may influence systemic lipid and energy metabolism. Our findings suggest that VNS could enhance neuronal function by modulating energy metabolism, thus potentially reducing seizure frequency in subjects with DRE. Future research targeting SIRT1 and PPARα may provide innovative therapeutic strategies for managing DRE. Plain Language Summary: The exact mechanism of VNS is still unknown. This study investigated the effects of VNS Therapy on energetic metabolism, suggesting possible novel biomarkers for DRE subjects and neuromodulation therapies.

Indexed as

Drug Resistant EpilepsyVagus Nerve StimulationFatty AcidsHumansPPAR alphaQuality of LifeSeizuresSirtuin 1Fatty AcidsPPAR alphaSirtuin 1bioactive moleculesenergy and lipid metabolismfatty acidsneuromodulationPPARαSIRT1

Identifiers

PMID38016924
PMCPMC10839364
OpenAlexW4389108413

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.